Clinical trials: Antipsychotic Induced Weight Gain
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Intellectual Disability, Developmental Disability
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease.
- Conditions
- Intellectual Disability, Developmental Disability, Obesity
- Trial name
- METIDD (NCT05744479)
- Testing
- Metformin, Lifestyle Intervention
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Weight Gain
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
Lifestyle intervention and certain medications have been shown to be effective for antipsychotic-induced weight gain, but no controlled studies have compared psychological and pharmacological therapies.
- Trial name
- NCT00451399
- Testing
- metformin, lifestyle intervention
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Central South University
Hyperprolactinemia, Weight Gain
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
- Conditions
- Hyperprolactinemia, Weight Gain, Dyslipidemia
- Trial name
- NCT00541554
- Testing
- Abilify (aripiprazole)
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Antipsychotic Induced Weight Gain
: EFFECT OF PROBIOTIC SUPPLEMENTATION ON ATYPICAL ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS ATTENDING PSYCHIATRIC CLINICS AT AINSHAMS UNIVERSITY HOSPITALS (A RANDOMIZED CONTROLLED TRIAL)
the goal of the study is to improve the quality of life of patients on antipsychotic medications and increase the rate of compliance to treatment.
- Trial name
- NCT06936137
- Testing
- lactobacillus LS
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Ain Shams University
Weight Gain
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme
Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associated with weight gain .
- Trial name
- NCT00191828
- Testing
- olanzapine
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.
- Trial name
- METS (NCT00816907)
- Testing
- Metformin
- Where
- 16 sites in United States
- Volunteers
- 146 people
- Sponsor
- National Institute of Mental Health (NIMH)
Autism Spectrum Disorder
A Study Looking at How Well Children With Autism Spectrum Disorder on Medications Like Having More Protein
Antipsychotic medications are commonly prescribed in children and adults with ASD (Curtin, Jojic \& Bandini, 2014). But weight gain has been known to be one of the less desirable effects of these medications, increasing one's…
- Trial name
- NCT03708614
- Testing
- Controlled energy diet with elevated protein intake
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
Weight Gain, Antipsychotic Agents
Clozapine Induced Weight Gain
Clozapine is prescribed to patients with psychosis in whom other treatments have not worked. Research has shown, however, that clozapine may be associated with weight gain and abnormal blood sugar levels in some patients.
- Conditions
- Weight Gain, Antipsychotic Agents, Pharmacogenetics
- Trial name
- NCT03996356
- Testing
- No study intervention - observational study
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Cwm Taf University Health Board (NHS)
Obesity
Proper Nutrition, Physical Exercise and Appropriate Weight in Individuals With Long Term Mental Illness
Based on previous findings that mentally ill inpatients are interested in losing treatment associate weight gain and are capable of adhering to a weight reduction program, this study will investigate the effects of participation…
- Trial name
- NCT00474227
- Testing
- group therapy, physical exercise, nutrition lectures
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Lev-Hasharon Mental Healtlh Center
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
The study attempts to evaluate a histamine analog long used for the treatment of Meniere's disease, betahistine, that shows promise in reversing the antihistaminergic effects thought to be involved in antipsychotic induced weight…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder
- Trial name
- NCT00709202
- Testing
- Betahistine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Weight Gain
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount…
- Trial name
- PREVENT (NCT00617240)
- Testing
- metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients
In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.
- Trial name
- NCT01043250
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Samsung Medical Center
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Antipsychotic Induced Weight Gain
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. Furthermore, it is reported significant changes in food intake happened in patients with weight gain after intaking…
- Trial name
- dTMS (NCT07805980)
- Testing
- Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Xiangya Hospital of Central South University
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants.
- Trial name
- NCT05712265
- Testing
- Miricorilant, Fluvoxamine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Treatment Resistant Schizophrenia, Obesity & Overweight
Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects
The primary objective of the study is to assess the efficacy and tolerability of a 90-day daily supplementation with a Nitraria retusa dried crushed leaves infusion on the iatrogenic metabolic side effects induced in patients…
- Conditions
- Treatment Resistant Schizophrenia, Obesity & Overweight, Abdominal Obesity
- Trial name
- NCT07817069
- Testing
- The Nitraria retusa arm
- Where
- Tunisia
- Volunteers
- 30 people
- Sponsor
- Faculty of Medicine, Sousse
Schizophrenia Spectrum, Schizophrenia
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain.
- Conditions
- Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
- Trial name
- dTMS (NCT07795554)
- Testing
- dTMS of accelerated intermittent theta burst stimulation, ACC-iTBS
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Xiangya Hospital of Central South University